{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219507","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2026-05-12T20:17:39+00:00","discovered_at":"2026-05-12T20:19:00.336182+00:00","generated_at":"2026-05-12T20:31:44.872277+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atea Q1 net loss $45.4M ($0.57/shr); HCV Phase 3 topline mid-2026","bullets":["Net loss $45.4M vs $34.3M YoY; R&D spend rose to $41.1M on HCV Phase 3 and HEV preclinical.","Cash, equivalents & marketable securities $256.0M at March 31, 2026, down from $301.8M at Dec 2025.","C-BEYOND HCV Phase 3 (North America) enrollment completed; topline results expected mid-2026.","C-FORWARD HCV Phase 3 (ex-North America) enrollment on track to complete mid-2026; topline around year-end 2026.","HEV program: AT-587 selected as lead; in vitro data 30-150x more potent than sofosbuvir/ribavirin; Phase 1 initiation planned mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219507","json":"https://secwatch.observer/filing/0001193125-26-219507.json","markdown":"https://secwatch.observer/filing/0001193125-26-219507.md","text":"https://secwatch.observer/filing/0001193125-26-219507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312526219507/0001193125-26-219507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312526219507/d12234d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T20:31:44.872277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc928d657a774e95cc5188d1349940a2f3d82856","claim":"Atea Pharmaceuticals, Inc. reported financial results for for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 12, 2026, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312526219507/0001193125-26-219507-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}